Medicus Pharma (MDCX): De‑Risking Drug Development to Capture a High‑Growth Market Opportunity

In this episode of WTR Healthcare Happenings, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX), joins Tim Gerdeman and Robert Sassoon to walk through the company’s strategy and market focus. Dr. Bokhari explains how Medicus Pharma acquires mid‑stage drug assets with existing data, reducing development risk and positioning the company for potential partnerships with larger pharmaceutical players.The conversation highlights Medicus Pharma’s two lead programs aimed at major, established markets—including treatments for skin cancer and prostate‑related conditions, both representing large patient populations and significant commercial demand. Dr. Bokhari also discusses how the company is using generative AI to speed decision‑making, along with upcoming milestones and opportunities to secure non‑dilutive funding through out‑licensing.